Compare Arqit Quantum Inc (ARQQ) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arqit Quantum Inc vs BioNTech SE - ADR — how do they compare? Arqit Quantum Inc trades at $17.56 (market cap $332.04M), while BioNTech SE - ADR trades at $91.85 (market cap $23.14B). The key difference: BioNTech SE - ADR is far larger — about 69.7× Arqit Quantum Inc's market cap, and BioNTech SE - ADR is trading nearer its 52-week high, Arqit Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ARQQ | BNTX | |
|---|---|---|
Market Cap | $332.04M | $23.14B |
Sector | Technology | Health |
52-Week High | $58.27 | $119.34 |
52-Week Low | $11.78 | $83.89 |
Enterprise Value | $305.35M | $6.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARQQ trades at $19.08, down 6.79% today, with a bearish technical signal from moving averages. The company reported $530K revenue for 2025 but a net loss of $35.34M, with negative profit margins and high valuation ratios. Recent news highlights contract wins and 829% YoY revenue growth in H1 FY26, though earnings misses persist.
Outlook remains speculative given deep losses and high P/S of 275.84, but growth in quantum security deals offers potential. Key risks include cash burn and competitive threats. Analyst consensus is split 50/50 buy/hold, indicating cautious optimism amid fundamental challenges.
BNTX trades at $91.49, down 1.6% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $1.14 billion for 2025, with revenue of $2.87 billion, and is undergoing a strategic shift toward oncology, including a $1 billion share buyback and manufacturing site closures affecting 1,860 jobs. Analyst consensus is strongly bullish with a $129.67 price target.
The outlook hinges on BioNTech's transition from COVID-19 vaccine dependency to oncology pipeline success. Opportunities include a strong cash position of $16.78 billion and promising clinical data, but risks involve execution challenges, sustained losses, and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
